Martin Gutierrez, MD
Medical Oncology · Hackensack, NJNPI 1558562793
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,470 of the $38,456 with a category attached, or 76.6%. It is spread thinly across 37 manufacturers, the largest accounting for just 21.3%.
Across 172 payments — averaging $223.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8K
- Sanofi US Services Inc.$8K
- E.r. Squibb & Sons, L.L.C.$7K
- Incyte Corporation$6K
- Celularity Inc.$2K
- Eisai Inc.$2K
- plus $5K from 31 others
Across 4,877 payments — averaging $8570.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$12M
- Merck$10.7M
- Incyte Corporation$7.8M
- Sanofi US Services Inc.$1.4M
- Daiichi Sankyo Inc.$1.2M
- Pfizer$1M
- plus $7.7M from 32 others
What the payments were for
- Consulting fees$29,47077%
- Speaking & faculty fees$9943%
- Travel & lodging$3,75710%
- Food & beverage$4,09211%
- Education$1430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $8,194 |
| Sanofi US Services Inc. | 6 | $7,636 |
| E.r. Squibb & Sons, L.L.C. | 34 | $7,309 |
| Incyte Corporation | 2 | $6,304 |
| Celularity Inc. | 4 | $2,098 |
| Eisai Inc. | 5 | $2,070 |
| Boehringer Ingelheim International GmbH | 2 | $994 |
| Regeneron | 7 | $898 |
| Modernatx, Inc. | 2 | $856 |
| Mirati Therapeutics, Inc. | 13 | $310 |
| Beigene USA, Inc. | 4 | $225 |
| Seagen Inc. | 2 | $195 |
| Array Biopharma Inc | 12 | $171 |
| AstraZeneca | 2 | $152 |
| Ipsen Biopharmaceuticals, Inc | 8 | $136 |
| Pfizer | 10 | $127 |
| Gilead | 1 | $118 |
| AbbVie | 7 | $102 |
| Johnson & Johnson | 5 | $85 |
| Novartis | 5 | $78 |
| Amgen | 3 | $42 |
| Genentech USA, Inc. | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Deciphera Pharmaceuticals Inc. | 2 | $33 |
| Blueprint Medicines Corporation | 2 | $30 |
| Taiho Oncology, Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Tempus AI, Inc | 1 | $17 |
| EMD Serono, Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Servier Pharmaceuticals LLC | 1 | $13 |
| Boehringer Ingelheim | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,456 in reported general payments places this provider in the 85th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 46 | $757,348 |
| LonsurfTrifluridine/Tipiracil Hcl | 16 | $118,818 |
| CreonLipase/Protease/Amylase | 11 | $33,270 |
| ZenpepLipase/Protease/Amylase | 13 | $30,557 |
| EliquisApixaban | 26 | $15,899 |
| XareltoRivaroxaban | 14 | $7,577 |
| Imatinib Mesylate | 18 | $6,441 |
| Ondansetron Hcl | 126 | $2,506 |
| Prochlorperazine Maleate | 105 | $2,485 |
| Pantoprazole Sodium | 41 | $399 |
| Doxycycline Hyclate | 17 | $384 |
| Olanzapine | 29 | $366 |
| Dexamethasone | 16 | $290 |
| Ondansetron OdtOndansetron | 14 | $173 |
| LoperamideLoperamide Hcl | 13 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $152 | $757,34846 claims |
| Taiho Oncology, Inc.Lonsurf | $23 | $118,81816 claims |
| AbbVieCreon | $102 | $33,27011 claims |
| PfizerEliquis | $127 | $15,89926 claims |
| Johnson & JohnsonXarelto | $85 | $7,57714 claims |
| Lilly USA, LLCOlanzapine | $14 | $36629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Hackensack
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.